



BEST AVAILABLE COPY

Atty Docket No. ST98033-US

PATENT

DEC 17 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

19
15
5-29-03

In re application of:

Emmanuel CONSEILLER *et al.*

Appl. No.: 09/829,936

Filed: April 11, 2001

For: POLYPEPTIDE (MBP1) CAPABLE OF
INTERACTING WITH ONCOGENIC
MUTANTS OF THE P53 PROTEIN

Art Unit: 1642

Examiner: Sheela Jitendra Huff

Assistant Commissioner for Patents
Washington, D.C. 200231

Sir:

REPLY TO RESTRICTION REQUIREMENT

In response to the Communication dated November 14, 2002 (Paper No. 17), applicants elect to prosecute the claims in Group IV, claims 31 and 33, drawn to a polypeptide containing all or part of SEQ ID No. 22, with traverse.

REMARKS

The Examiner indicated in the Interview Summary that the Restriction Requirement dated June 20, 2002, recited the incorrect claims in Group IV. Applicants hereby elect to prosecute claims 31 and 33 of Group IV.

Applicants respectfully traverse the requirement for restriction and the requirement to select a single nucleotide sequence for examination. The reasons for applicants' traversal were set forth in the Reply to Restriction Requirement filed on September 19, 2002, which are specifically incorporated herein by reference. The Patent Office has yet to respond to these reasons.